Ticker League

Cash on Hand for Vertex Pharmaceuticals (VRTX)

As of · Reported

Metric

Latest period

$7.25B

YoY change

+8.1%

5Y CAGR

-0.1%

Peak year (2023)

$11.22B

Cash on Hand history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: $6.61B

Cash on Hand growth chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: +8.1%

Cash on Hand history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

  • 2025$6.61B+8.1%
  • 2024$6.12B-45.5%
  • 2023$11.22B+4.1%
  • 2022$10.78B+43.2%
  • 2021$7.52B+13.0%
  • 2020$6.66B+74.9%
  • 2019$3.81B+20.2%
  • 2018$3.17B+51.7%
  • 2017$2.09B+45.6%
  • 2016$1.43B+37.6%
  • 2015$1.04B-24.8%
  • 2014$1.39B-5.3%
  • 2013$1.47B+10.9%
  • 2012$1.32B+36.4%
  • 2011$968.92M-6.1%
  • 2010$1.03B-19.7%
  • 2009$1.28B+54.4%
  • 2008$832.10M+80.5%
  • 2007$460.87M-34.6%
  • 2006$704.63M+95.1%
  • 2005$361.16M-6.5%
  • 2004$386.25M-33.8%
  • 2003$583.16M-8.2%
  • 2002$634.98M-14.6%
  • 2001$743.20M+61.6%
  • 2000$459.92M+144.9%
  • 1999$187.80M+676.0%
  • 1998$24.20M-66.2%
  • 1997$71.50M+104.9%
  • 1996$34.90M+22.9%
  • 1995$28.40M-60.3%
  • 1994$71.60M+150.3%
  • 1993$28.60M+146.6%
  • 1992$11.60M-58.0%
  • 1991$27.60M+527.3%
  • 1990$4.40M—

Cash on Hand values are taken from Vertex Pharmaceuticals's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Cash on Hand at Vertex Pharmaceuticals (VRTX)

According to Vertex Pharmaceuticals's latest reported financial statements, the company's latest reported cash and short-term investments is $7.25B. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

2025's annual cash and short-term investments for Vertex Pharmaceuticals (VRTX) came in at $6.61B – grew 8.1% year-over-year.

Vertex Pharmaceuticals cash and short-term investments compound annual growth for the 2020–2025 (5 years) window is -0.1%, with a net decline across the window.

Vertex Pharmaceuticals cash and short-term investments peaked at $11.22B in 2023; the latest annual figure is $6.61B in 2025 (41.1% below peak).

The highest annual cash and short-term investments of $11.22B was reported in 2023. The lowest in the available history was $4.40M in 1990.

Vertex Pharmaceuticals Cash on Hand by Year

Vertex Pharmaceuticals Cash on Hand 2025: $6.61B

Vertex Pharmaceuticals cash and short-term investments in 2025 was $6.61B, grew 8.1% from 2024.

Vertex Pharmaceuticals Cash on Hand 2024: $6.12B

2024's cash and short-term investments for Vertex Pharmaceuticals came in at $6.12B, plunged 45.5% below 2023.

Vertex Pharmaceuticals Cash on Hand 2023: $11.22B

Vertex Pharmaceuticals posted cash and short-term investments of $11.22B in 2023, edged up 4.1% from 2022. This figure represents the highest annual value in the available history.

Vertex Pharmaceuticals Cash on Hand 2022: $10.78B

In 2022, Vertex Pharmaceuticals reported cash and short-term investments of $10.78B, surged 43.2% from 2021.

Vertex Pharmaceuticals Cash on Hand 2021: $7.52B

Vertex Pharmaceuticals cash and short-term investments in 2021 was $7.52B.

See more financial history for Vertex Pharmaceuticals (VRTX).

Sector peers by Cash on Hand

Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by their latest cash and short-term investments

Frequently asked questions

Vertex Pharmaceuticals (VRTX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation